Ansell Cap Corp (ANCCF) 0.1897 $ANCCF
BriaCell Launches Development of Companion Diagnostic Product, BriaDx(TM)
Marketwired - Mon Sep 14, 8:30AM CDT
BriaCell Therapeutics Corp (OTCQB: ANCCF) (TSX VENTURE: BCT) ("BriaCell", the "Company", or "BCT"
is pleased to announce the initiation of its key research and development program pertaining to BriaCell's novel companion diagnostic product, which is to be called "BriaDx(TM)".
BCT.VN: 0.175 (unch)
Immuno-Oncology Biotech BriaCell Attracts Top Scientist to Head R&D
Marketwired - Wed Jul 15, 8:03AM CDT
BriaCell Therapeutics Corp (OTCQB: ANCCF) (TSX VENTURE: BCT) ("BriaCell", the "Company", or "BCT" announced today that Markus Lacher, Ph.D. has been appointed as Senior Director, Research and Development. Dr. Lacher will immediately assume all responsibility for the development and execution of all research and process development plans for the Company's lead product, BriaVax(TM), a cell-based cancer immunotherapy. In addition, Dr. Lacher will also assume responsibility for analyzing samples obtained from patients treated in the Company's upcoming Phase I/II clinical trial. Having served in a senior scientific role in the development programs of numerous cell therapy and diagnostic products, Dr. Lacher brings to BriaCell extensive experience within the biotechnology industry.
BCT.VN: 0.175 (unch)
BriaCell Therapeutics Begins Trading on the OTCQB (ANCCF) and Presents at a New York Biotech Investor Conference
Marketwired - Wed Jun 24, 8:30AM CDT
BriaCell Therapeutics Corp (TSX VENTURE: BCT) (OTCQB: ANCCF) ("BriaCell", the "Company", or "BCT", a clinical stage cancer immunotherapy company, has been approved to begin trading today on the OTCQB® Marketplace in the United States under the symbol "ANCCF". The Company will continue to trade on the Toronto Stock Exchange Venture under the symbol "BCT".
BCT.VN: 0.175 (unch)
BriaCell Therapeutics Announces Closing of Go-Public Onto Toronto Stock Exchange Venture, Closing of Concurrent Financing With Agents Sunel Securities and M Partners, Closing of Hospital Partnership and Royalty Relinquishment Corporate Update
GlobeNewswire - Wed Dec 03, 11:26AM CST
BriaCell Therapeutics Corp (TSX-V:BCT) ("BriaCell", the "Company", or "BCT" is pleased to announce that it has, effective December 1, 2014, completed its Go-Public Event onto the Toronto Stock Exchange Venture (the "Go-Public" and concurrent financing (the "Financing" (together referred to as the "Transaction" with Ansell Capital Corp ("Ansell". The Company's shares are now trading under the symbol BCT. The terms of the Go-Public Event, which was structured as a Reverse Takeover ("RTO" under the rules and policies of the TSX Venture Exchange (the "TSX-V", were previously announced by the Company in a release dated April 17, 2014. The Transaction was approved by 100.00% of shareholders. At a deemed value of $0.18 the Company's market value is approximately $15 million.
BCT.VN: 0.175 (unch)
IIROC Trading Resumption - BCT
CNW Group - Tue Dec 02, 3:12PM CST
Trading resumes in:
BriaCell Launches Development of Companion Diagnostic Product, BriaDx(TM)
Marketwired - Mon Sep 14, 8:30AM CDT
BriaCell Therapeutics Corp (OTCQB: ANCCF) (TSX VENTURE: BCT) ("BriaCell", the "Company", or "BCT"
is pleased to announce the initiation of its key research and development program pertaining to BriaCell's novel companion diagnostic product, which is to be called "BriaDx(TM)". BCT.VN: 0.175 (unch)
Immuno-Oncology Biotech BriaCell Attracts Top Scientist to Head R&D
Marketwired - Wed Jul 15, 8:03AM CDT
BriaCell Therapeutics Corp (OTCQB: ANCCF) (TSX VENTURE: BCT) ("BriaCell", the "Company", or "BCT"
announced today that Markus Lacher, Ph.D. has been appointed as Senior Director, Research and Development. Dr. Lacher will immediately assume all responsibility for the development and execution of all research and process development plans for the Company's lead product, BriaVax(TM), a cell-based cancer immunotherapy. In addition, Dr. Lacher will also assume responsibility for analyzing samples obtained from patients treated in the Company's upcoming Phase I/II clinical trial. Having served in a senior scientific role in the development programs of numerous cell therapy and diagnostic products, Dr. Lacher brings to BriaCell extensive experience within the biotechnology industry. BCT.VN: 0.175 (unch)
BriaCell Therapeutics Begins Trading on the OTCQB (ANCCF) and Presents at a New York Biotech Investor Conference
Marketwired - Wed Jun 24, 8:30AM CDT
BriaCell Therapeutics Corp (TSX VENTURE: BCT) (OTCQB: ANCCF) ("BriaCell", the "Company", or "BCT"
, a clinical stage cancer immunotherapy company, has been approved to begin trading today on the OTCQB® Marketplace in the United States under the symbol "ANCCF". The Company will continue to trade on the Toronto Stock Exchange Venture under the symbol "BCT". BCT.VN: 0.175 (unch)
BriaCell Therapeutics Announces Closing of Go-Public Onto Toronto Stock Exchange Venture, Closing of Concurrent Financing With Agents Sunel Securities and M Partners, Closing of Hospital Partnership and Royalty Relinquishment Corporate Update
GlobeNewswire - Wed Dec 03, 11:26AM CST
BriaCell Therapeutics Corp (TSX-V:BCT) ("BriaCell", the "Company", or "BCT"
is pleased to announce that it has, effective December 1, 2014, completed its Go-Public Event onto the Toronto Stock Exchange Venture (the "Go-Public" and concurrent financing (the "Financing" (together referred to as the "Transaction" with Ansell Capital Corp ("Ansell". The Company's shares are now trading under the symbol BCT. The terms of the Go-Public Event, which was structured as a Reverse Takeover ("RTO" under the rules and policies of the TSX Venture Exchange (the "TSX-V", were previously announced by the Company in a release dated April 17, 2014. The Transaction was approved by 100.00% of shareholders. At a deemed value of $0.18 the Company's market value is approximately $15 million. BCT.VN: 0.175 (unch)
IIROC Trading Resumption - BCT
CNW Group - Tue Dec 02, 3:12PM CST
Trading resumes in:
